Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines

Gregory P. Holmes-Hampton, Daniel R. Crooks, Ronald G. Haller, Shuling Guo, Susan M. Freier, Brett P. Monia, Tracey A. Rouault

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


ISCU myopathy is an inherited disease that primarily affects individuals of northern Swedish descent who share a single point mutation in the fourth intron of the ISCU gene. The current study shows correction of specific phenotypes associated with disease following treatment with an antisense oligonucleotide (ASO) targeted to the site of the mutation. We have shown that ASO treatment diminished aberrant splicing and increased ISCU protein levels in both patient fibroblasts and patient myotubes in a concentration dependent fashion. Upon ASO treatment, levels of SDHB in patient myotubular cell lines increased to levels observed in control myotubular cell lines. Additionally, we have shown that both patient fibroblast and myotubular cell lines displayed an increase in complex II activity with a concomitant decrease in succinate levels in patient myotubular cell lines after ASO treatment. Mitochondrial and cytosolic aconitase activities increased significantly following ASO treatment in patient myotubes. The current study suggests that ASO treatment may serve as a viable approach to correcting ISCU myopathy in patients.

Original languageEnglish (US)
Pages (from-to)5178-5187
Number of pages10
JournalHuman molecular genetics
Issue number23
StatePublished - 2016

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Use of antisense oligonucleotides to correct the splicing error in ISCU myopathy patient cell lines'. Together they form a unique fingerprint.

Cite this